Precision Medicine and Artificial Intelligence – The Perfect Fit for Autoimmunity
A new book ‘Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity‘ with Academic Press /Elsevier Science Publishing Co Inc; editor Michael Mahler was co-authored by IAG’s CEO Dr Olga Kubassova, and collaborators Dr. Faiq Shaikh and Dr. Michael Mahler, who contributed to the chapter ‘History, current status and future directions of Artificial Intelligence’.
Book: Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity
Access Online: https://www.elsevier.com/
Published: 31 March 2021
Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity covers background on artificial intelligence (AI), its link to precision medicine (PM), and examples of AI in healthcare, especially autoimmunity. The book highlights future perspectives and potential directions as AI has gained significant attention during the past decade. Autoimmune diseases are complex and heterogeneous conditions, but exciting new developments and implementation tactics surrounding automated systems have enabled the generation of large datasets, making autoimmunity an ideal target for AI and precision medicine.
More and more diagnostic products utilize AI, which is also starting to be supported by regulatory agencies such as the Food and Drug Administration (FDA). Knowledge generation by leveraging large datasets including demographic, environmental, clinical and biomarker data has the potential to not only impact the diagnosis of patients, but also disease prediction, prognosis and treatment options.
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.
Reach out to our expert team to discuss your development programs: email@example.com